Volume 1, Issue 13


Cover Image

Cover Figure: Cy3–miRNA-340 signals (red) detected in the cytoplasm of RPMI8226-HR cells.
See the article by Umezu et al.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, May 23,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Cold agglutinin disease (CAD) is a hemolytic anemia characterized by the development of autoreactive antibodies that bind to red blood cells at low temperatures. CAD can be challenging to properly diagnose and treat. In this study by Mullins et al, a cohort of patients with CAD were studied longitudinally, documenting the relapsing and remitting course of these patients over time. Many of these patients required multiple therapies and frequent follow-up. Clearly, better treatments are needed for this rare but at times devastating disorder.

Hemophilia A and B are life-threatening bleeding disorders. To better understand this X-linked disorder, the My Life, Our Future initiative was formed to characterize and study the genetics of hemophilia. In this analysis, 3000 hemophilia patients were studied molecularly, with many variants identified. This analysis and others like it will serve as important data sets and biorepositories to study this and other genetic disorders.

Transplantation for low-risk patients with severe thalassemia has been very successful, with over 80% of low-risk children likely cured of their disease. The standard approach has been to use busulfan and cyclophosphamide; however, some centers have experienced high rejection rates. In this report by Faulkner et al the addition of either thiotepa or ATG is evaluated, with interesting results.

Featured Visual Abstract

Sphingomyelin encrypts tissue factor: ATP-induced activation of A-SMase leads to tissue factor decryption and microvesicle shedding

Jue Wang, Usha R. Pendurthi, L. Vijaya Mohan Rao





Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.